ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)

ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)

<p><strong>Background</strong> This randomized phase 2 trial compared the efficacy and safety of second‐line nanoparticle albumin‐bound paclitaxel (nab‐paclitaxel) with or without the addition of CC‐486 (an oral formulation of 5‐azacytidine) in patients with advanced‐stage, nonsqua...

Bibliográfalaš dieđut
Váldodahkkit:	Morgensztern, D, Cobo, M, Ponce Aix, S, Postmus, PE, Lewanski, CR, Bennouna, J, Fischer, JR, Juan-Vidal, O, Stewart, DJ, Fasola, G, Ardizzoni, A, Bhore, R, Wolfsteiner, M, Talbot, DC, Jin Ong, T, Govindan, R, On Behalf Of The Abound L Investigators
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	Wiley 2018

Geahča maid

ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)
Dahkki: Morgensztern, D, et al.
Almmustuhtton: (2017)

Efficacy and safety of second- or third-line nab-paclitaxel + durvalumab in patients with advanced NSCLC (ABOUND.2L+)
Dahkki: Morgensztern, D, et al.
Almmustuhtton: (2018)

Quality of life in patients with advanced NSCLC treated in second- or third-line with nab-paclitaxel + durvalumab: abound.2l+
Dahkki: Talbot, D, et al.
Almmustuhtton: (2018)

Nab-paclitaxel + durvalumab as second- or third-line treatment of advanced NSCLC: results from ABOUND.2l+
Dahkki: Govindan, R, et al.
Almmustuhtton: (2017)

nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)
Dahkki: Daniel Morgensztern, et al.
Almmustuhtton: (2021-02-01)

Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer
Dahkki: Ponce Aix, S, et al.
Almmustuhtton: (2020)

nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC
Dahkki: Corey J. Langer, et al.
Almmustuhtton: (2018-07-01)

nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis
Dahkki: Corey J. Langer, et al.
Almmustuhtton: (2021-01-01)

Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.
Dahkki: Eric Laille, et al.
Almmustuhtton: (2015-01-01)

nab-Paclitaxel–Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2
Dahkki: Ajeet Gajra, et al.
Almmustuhtton: (2018-07-01)

The uses of anxiety: Grace Abounding to the Chief of Sinners (1666)
Dahkki: Seymour, L
Almmustuhtton: (2023)

Short Toxin-like Proteins Abound in Cnidaria Genomes
Dahkki: Michal Linial, et al.
Almmustuhtton: (2012-11-01)

Misperceptions of "light" cigarettes abound: National survey data
Dahkki: Thomson George, et al.
Almmustuhtton: (2009-05-01)

Aboundance, Diversity and Distribution of Ichthyoplanktons in Creeks and Coastal Waters of Khouzestan Province
Dahkki: S. Dehghan; A. Savari; P. Kochenin; J. Ghafle marammazi
Almmustuhtton: (1999-01-01)

The Jurisdictional Basis, Elements and Remedies in the Action for Breach of Confidence - Uncertainty Abounds
Dahkki: Leo Tsaknis

Features of fibrosis regression abound in "non-cirrhotic" patients with resected hepatocellular carcinoma.
Dahkki: Christine E Orr, et al.
Almmustuhtton: (2022-01-01)

Improbabilities abound”: Daphne du Maurier’s Rule Britannia and the speculative political future
Dahkki: Aoife Byrne
Almmustuhtton: (2015-07-01)

Features of fibrosis regression abound in “non-cirrhotic” patients with resected hepatocellular carcinoma
Dahkki: Christine E. Orr, et al.
Almmustuhtton: (2022-01-01)

Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC
Dahkki: Véronique Hofman, MD, PhD, et al.
Almmustuhtton: (2023-02-01)

Phase III, randomized, placebo-controlled trial of CC-486 (Oral Azacitidine) in patients with lower-risk myelodysplastic syndromes
Dahkki: Garcia-Manero, G, et al.
Almmustuhtton: (2021)

An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors
Dahkki: Neda Stjepanovic, et al.
Almmustuhtton: (2020-10-01)

Exodus, Psalms and Hebrews: A God abounding in steadfast love (Ex 34:6)
Dahkki: Alphonso Groenewald
Almmustuhtton: (2008-03-01)

Efficacy of paclitaxel‐carboplatin with bevacizumab as a late‐line therapy for patients with advanced nonsquamous non‐small cell lung cancer: A platinum rechallenge
Dahkki: Jun Sugisaka, et al.
Almmustuhtton: (2023-11-01)

Ticks and Tick-Borne Pathogens Abound in the Cattle Population of the Rabat-Sale Kenitra Region, Morocco
Dahkki: Latifa Elhachimi, et al.
Almmustuhtton: (2021-12-01)

Soils rich in biological ice-nucleating particles abound in ice-nucleating macromolecules likely produced by fungi
Dahkki: F. Conen, et al.
Almmustuhtton: (2018-07-01)

Length Frequency, Sex Ratio and Relative Aboundance (CPUE) of Astacus leptoductylus in Arass Reservior (1997-98)
Dahkki: M. Karimpor; N. Hosseinpor
Almmustuhtton: (1999-01-01)

Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial
Dahkki: Yoshimasa Shiraishi, et al.
Almmustuhtton: (2022-09-01)

Computer processor unit 486
Dahkki: Universiti Teknologi Malaysia. Perpustakaan
Almmustuhtton: (1989)

nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial
Dahkki: Gridelli C, et al.
Almmustuhtton: (2018-05-01)

Androgen Receptor Expression in Primary Nonsquamous Cell Rare-Variant Carcinomas of the Head and Neck
Dahkki: Siavash Rahimi MD, FRCPath, et al.
Almmustuhtton: (2017-06-01)

Multicenter study of carbon‐ion radiation therapy for nonsquamous cell carcinomas of the oral cavity
Dahkki: Hiroaki Ikawa, et al.
Almmustuhtton: (2019-09-01)

A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC
Dahkki: Daichi Fujimoto, MD, et al.
Almmustuhtton: (2022-02-01)

Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous Non-Small Cell Lung Cancer
Dahkki: Hidetoshi Hayashi, et al.
Almmustuhtton: (2011-01-01)

P540: RESULTS FROM A PHASE 1 CLINICAL STUDY OF THE ALL-ORAL REGIMEN OF CC-486 AND VENETOCLAX FOR RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
Dahkki: Maria Amaya, et al.
Almmustuhtton: (2023-08-01)

KIE 486 - KIMIA MAKANAN JUN 1994.
Dahkki: PPSK, Pusat Pengajian Sains Kimia
Almmustuhtton: (1994)

Brief Report: Impact of Maintenance Pemetrexed Cessation on Clinical Outcomes of Patients With Metastatic Nonsquamous NSCLC
Dahkki: Shreya Bhatia, BS, et al.
Almmustuhtton: (2024-11-01)

Biomarker Testing for Patients With Advanced/Metastatic Nonsquamous NSCLC in the United States of America, 2015 to 2021
Dahkki: Lisa M. Hess, PhD, et al.
Almmustuhtton: (2022-06-01)

Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience
Dahkki: Laurent Greillier, et al.
Almmustuhtton: (2016-10-01)

An Epidemiologic study of Oral and Pharyngeal Nonsquamous Cell Malignant Tumors inKerman province, Iran
Dahkki: MR. Zarei, et al.
Almmustuhtton: (2007-03-01)

Glenn's Suzuki one-cylinder repair and tune-up guide : models 50 cc, 55 cc, 80 cc, 90 cc, 120 cc, 125 cc, 185 cc, 250 cc, 400 cc/
Dahkki: 402466 Crawford, Charles W., et al.
Almmustuhtton: (1972)